35 /100
MEDIUM RISK
Score updated Jul 14, 2026

TBPH — Theravance Biopharma, Inc. Dilution Risk Tracker

Track TBPH dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track TBPH — Get alerts when the score changes →

As of July 14, 2026, Theravance Biopharma, Inc. (TBPH) has a DilutionWatch DilutionScore of 35/100, rated MEDIUM dilution risk. Theravance Biopharma, Inc. has a market capitalization of $827.94M, 51.55M shares outstanding, 174 institutional holders tracked. Key dilution vectors include approximately 999 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
40
💰 Cash Runway
0
📊 Float Risk
65
⚠️ Warrant Exposure
40
🔄Convertible Debt

🌦️ Dilution Forecast

🌥️
Advisory
Moderate dilution signals present
20%
🔁 Convertible Conversion 40%
• Significant convertible debt: 28% potential dilution
• Elevated convertible risk (60/100)
🔔 Track TBPH — Get forecast alerts →

💹 Market Data

Market Cap$827.94M
Shares Outstanding51.55M
Float23.70M
Cash$288.10M
Debt$40.50M
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 9.1% shares (2026Q1 vs prior)
174 institutional holders · 55.11M shares
#1 Madison Avenue Partners, LP 9.51M shares
#2 Weiss Asset Management LP 7.46M shares
#3 Newtyn Management, LLC 4.84M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest4.50M
Days to Cover4.2
% of Float19.0%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL CONVERTIBLE Jun 30, 2022
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for TBPH Shareholders

Theravance Biopharma, Inc. (TBPH) has a DilutionScore of 35/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 14, 2026.

DilutionWatch's EDGAR monitoring for TBPH shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for TBPH in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for TBPH alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track TBPH Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking TBPH — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for TBPH
📊 TBPH FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 TBPH Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.